[{"id":"f98e10ef-ecf5-4a3d-b5b3-240b7e0bd849","acronym":"","url":"https://clinicaltrials.gov/study/NCT06439836","created_at":"2024-06-08T04:14:47.148Z","updated_at":"2025-02-25T14:11:06.436Z","phase":"Phase 1","brief_title":"Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy","source_id_and_acronym":"NCT06439836","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD68 • CRP","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • CD68 • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • emavusertib (CA-4948)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 02/21/2025","start_date":" 02/21/2025","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-18"},{"id":"ecd3b97e-f85f-4235-ac7a-4003f3339215","acronym":"NEOpredict-EGF","url":"https://clinicaltrials.gov/study/NCT06784791","created_at":"2025-02-25T14:44:13.644Z","updated_at":"2025-02-25T14:44:13.644Z","phase":"Phase 2","brief_title":"Preoperative Amivantamab or Amivantamab and Carboplatin/pemetrexed Treatment in Patients with Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)","source_id_and_acronym":"NCT06784791 - NEOpredict-EGF","lead_sponsor":"University Hospital, Essen","biomarkers":" EGFR • CD8 • CD163 • CD4 • NCAM1 • CD68","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR • CD8 • CD163 • CD4 • NCAM1 • CD68"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/06/2024","start_date":" 11/06/2024","primary_txt":" Primary completion: 07/31/2027","primary_completion_date":" 07/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-14"},{"id":"2617ca5f-47d4-4a37-a652-3e4d4a06848f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03347838","created_at":"2023-11-29T17:14:43.874Z","updated_at":"2025-02-25T14:37:43.448Z","phase":"Phase 2","brief_title":"Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers","source_id_and_acronym":"NCT03347838","lead_sponsor":"University of Colorado, Denver","biomarkers":" PD-L1 • PD-1 • CD4 • CD68 • HLA-DRA • MRC1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • PD-1 • CD4 • CD68 • HLA-DRA • MRC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 01/30/2019","start_date":" 01/30/2019","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-09-25"},{"id":"245ed9e1-ca34-4788-8cc3-6546ba073450","acronym":"","url":"https://clinicaltrials.gov/study/NCT06573398","created_at":"2025-02-27T08:15:39.768Z","updated_at":"2025-02-27T08:15:39.768Z","phase":"Phase 2","brief_title":"Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC","source_id_and_acronym":"NCT06573398","lead_sponsor":"Ruijin Hospital","biomarkers":" CD8 • CD163 • CD4 • CD68 • CD86","pipe":"","alterations":" ","tags":["CD8 • CD163 • CD4 • CD68 • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • Zadaxin (thymalfasin)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/01/2024","start_date":" 09/01/2024","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-08-27"},{"id":"356e3601-303f-449c-86cb-daf647b519de","acronym":"","url":"https://clinicaltrials.gov/study/NCT06532539","created_at":"2025-02-25T16:28:03.858Z","updated_at":"2025-02-25T16:28:03.858Z","phase":"Phase 2","brief_title":"Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma","source_id_and_acronym":"NCT06532539","lead_sponsor":"Shandong Cancer Hospital and Institute","biomarkers":" CD8 • PD-1 • TIGIT • NCAM1 • STING • CD68 • PVR","pipe":"","alterations":" ","tags":["CD8 • PD-1 • TIGIT • NCAM1 • STING • CD68 • PVR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • Kaitanni (cadonilimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/13/2024","start_date":" 06/13/2024","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2024-08-01"},{"id":"c3c05277-42e5-4669-bea5-688ad1660501","acronym":"","url":"https://clinicaltrials.gov/study/NCT06001658","created_at":"2023-08-21T14:08:46.484Z","updated_at":"2025-02-25T16:19:01.820Z","phase":"Phase 2","brief_title":"Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers","source_id_and_acronym":"NCT06001658","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CD8 • CD163 • CD68","pipe":" | ","alterations":" ARG1 overexpression • CD163 expression","tags":["CD8 • CD163 • CD68"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ARG1 overexpression • CD163 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • gemcitabine"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 07/08/2024","start_date":" 07/08/2024","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2024-07-25"},{"id":"114d9c89-e0e5-473e-a324-f2022f9b4244","acronym":"","url":"https://clinicaltrials.gov/study/NCT04465643","created_at":"2021-01-18T21:27:49.677Z","updated_at":"2025-02-25T14:29:26.270Z","phase":"Phase 1","brief_title":"Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor","source_id_and_acronym":"NCT04465643","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" PD-L1 • CD20 • CD8 • PD-1 • LAG3 • CD276 • CTLA4 • PD-L2 • VTCN1 • HAVCR2 • IL2RA • CD163 • TIGIT • PTPRC • NCAM1 • ICOS • CD14 • CD68 • GZMB • ITGAM • BTLA • FOXP3 • MRC1 • ISG20","pipe":"","alterations":" ","tags":["PD-L1 • CD20 • CD8 • PD-1 • LAG3 • CD276 • CTLA4 • PD-L2 • VTCN1 • HAVCR2 • IL2RA • CD163 • TIGIT • PTPRC • NCAM1 • ICOS • CD14 • CD68 • GZMB • ITGAM • BTLA • FOXP3 • MRC1 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 06/08/2021","start_date":" 06/08/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-06-21"},{"id":"9059f5a8-2395-4548-8c8d-e5dd82620a3b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05836571","created_at":"2023-11-13T21:15:12.751Z","updated_at":"2024-07-02T16:34:37.937Z","phase":"Phase 2","brief_title":"Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People \u003e= 18 Years Old With Advanced Soft Tissue Sarcoma","source_id_and_acronym":"NCT05836571","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • CD68","pipe":"","alterations":" ","tags":["TMB • CD68"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Suspended","enrollment":" Enrollment 66","initiation":"Initiation: 10/25/2023","start_date":" 10/25/2023","primary_txt":" Primary completion: 05/15/2026","primary_completion_date":" 05/15/2026","study_txt":" Completion: 05/15/2026","study_completion_date":" 05/15/2026","last_update_posted":"2024-06-05"},{"id":"b2d0e16f-9f16-4b18-afd1-1b771c949f14","acronym":"","url":"https://clinicaltrials.gov/study/NCT05955105","created_at":"2024-05-21T20:33:37.710Z","updated_at":"2024-07-02T16:35:02.295Z","phase":"Phase 1/2","brief_title":"A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies","source_id_and_acronym":"NCT05955105","lead_sponsor":"Innolake Biopharm","biomarkers":" PD-L1 • TMB • MSI • CD8 • CD68","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • TMB • MSI • CD8 • CD68"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • ILB-2109"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 07/25/2023","start_date":" 07/25/2023","primary_txt":" Primary completion: 01/25/2026","primary_completion_date":" 01/25/2026","study_txt":" Completion: 07/24/2026","study_completion_date":" 07/24/2026","last_update_posted":"2024-05-21"},{"id":"94c8991a-5401-4521-bceb-f4667098ab6b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03035357","created_at":"2021-01-18T14:56:23.113Z","updated_at":"2024-07-02T16:35:06.269Z","phase":"Phase 2","brief_title":"Neoadjuvant Listeria or Daratumumab in Prostate Cancer","source_id_and_acronym":"NCT03035357","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD68","pipe":"","alterations":" ","tags":["CD68"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Darzalex (daratumumab)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/01/2017","start_date":" 03/01/2017","primary_txt":" Primary completion: 03/01/2019","primary_completion_date":" 03/01/2019","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2024-05-03"},{"id":"39769fed-659c-4bfe-8a22-cc44cf784049","acronym":"","url":"https://clinicaltrials.gov/study/NCT04541108","created_at":"2021-01-18T21:43:38.590Z","updated_at":"2024-07-02T16:35:08.887Z","phase":"Phase 1","brief_title":"Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies","source_id_and_acronym":"NCT04541108","lead_sponsor":"Presage Biosciences","biomarkers":" CD8 • TNFA • CD163 • CD4 • NCAM1 • CASP3 • CD68 • GZMB • CD86","pipe":"","alterations":" ","tags":["CD8 • TNFA • CD163 • CD4 • NCAM1 • CASP3 • CD68 • GZMB • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • paclitaxel • 5-fluorouracil • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • BMS-986299 • MK-0482 • MK-4830 • dazostinag (TAK-676) • sabestomig (AZD7789)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 07/26/2021","start_date":" 07/26/2021","primary_txt":" Primary completion: 12/01/2031","primary_completion_date":" 12/01/2031","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-04-18"},{"id":"83026695-d43a-4653-bca6-29f8b4ee5021","acronym":"REVOLUMAB","url":"https://clinicaltrials.gov/study/NCT03925246","created_at":"2021-01-18T19:18:33.109Z","updated_at":"2025-02-25T14:28:20.050Z","phase":"Phase 2","brief_title":"Efficacy of Nivolumab for Recurrent IDH Mutated High-Grade Gliomas","source_id_and_acronym":"NCT03925246 - REVOLUMAB","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" PD-L1 • TMB • IDH1 • IDH2 • MGMT • CD8 • PD-1 • ATRX • CD163 • CD4 • CD68 • FOXP3 • GFAP • OLIG2","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation • IDH1 R132","tags":["PD-L1 • TMB • IDH1 • IDH2 • MGMT • CD8 • PD-1 • ATRX • CD163 • CD4 • CD68 • FOXP3 • GFAP • OLIG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • temozolomide"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 07/30/2019","start_date":" 07/30/2019","primary_txt":" Primary completion: 12/02/2020","primary_completion_date":" 12/02/2020","study_txt":" Completion: 08/18/2021","study_completion_date":" 08/18/2021","last_update_posted":"2024-04-02"},{"id":"32402300-ed12-444a-8c26-2796065462cb","acronym":"Micros","url":"https://clinicaltrials.gov/study/NCT03737435","created_at":"2021-01-18T18:18:22.782Z","updated_at":"2024-07-02T16:35:13.275Z","phase":"","brief_title":"Tumor Microenvironment in Patients With Localized Osteosarcoma Treated With Mifamurtide: a Translational Study","source_id_and_acronym":"NCT03737435 - Micros","lead_sponsor":"Istituto Ortopedico Rizzoli","biomarkers":" PD-L1 • CD68","pipe":"","alterations":" ","tags":["PD-L1 • CD68"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mepact (mifamurtide)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 12/12/2018","start_date":" 12/12/2018","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-03-22"},{"id":"09d1fbdf-77a8-4bee-80bb-3ea81998914c","acronym":"EC-CRT-006","url":"https://clinicaltrials.gov/study/NCT06143748","created_at":"2023-11-22T20:17:12.091Z","updated_at":"2024-07-02T16:35:15.112Z","phase":"Phase 2","brief_title":"Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006)","source_id_and_acronym":"NCT06143748 - EC-CRT-006","lead_sponsor":"Sun Yat-sen University","biomarkers":" CD8 • CTLA4 • NCAM1 • CD68","pipe":"","alterations":" ","tags":["CD8 • CTLA4 • NCAM1 • CD68"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • paclitaxel • Kaitanni (cadonilimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 03/02/2024","start_date":" 03/02/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-03-12"},{"id":"adb47411-e4ca-44c0-af22-a98798c3a97a","acronym":"EC-CRT-007","url":"https://clinicaltrials.gov/study/NCT06187597","created_at":"2024-01-02T14:16:57.201Z","updated_at":"2024-07-02T16:35:15.221Z","phase":"Phase 2","brief_title":"Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)","source_id_and_acronym":"NCT06187597 - EC-CRT-007","lead_sponsor":"Sun Yat-sen University","biomarkers":" IL6 • CTLA4 • IL2RA • NCAM1 • CD68 • CD40","pipe":"","alterations":" ","tags":["IL6 • CTLA4 • IL2RA • NCAM1 • CD68 • CD40"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 03/01/2024","start_date":" 03/01/2024","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-03-12"},{"id":"1a870e3d-d1a5-4225-80df-e89da512381b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03013933","created_at":"2024-02-22T16:25:29.863Z","updated_at":"2024-07-02T16:35:18.227Z","phase":"Phase 1","brief_title":"Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma","source_id_and_acronym":"NCT03013933","lead_sponsor":"City of Hope Medical Center","biomarkers":" TNFRSF8 • CD68","pipe":"","alterations":" ","tags":["TNFRSF8 • CD68"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Adcetris (brentuximab vedotin) • cyclosporin A microemulsion"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 05/03/2017","start_date":" 05/03/2017","primary_txt":" Primary completion: 05/24/2022","primary_completion_date":" 05/24/2022","study_txt":" Completion: 05/24/2022","study_completion_date":" 05/24/2022","last_update_posted":"2024-02-22"},{"id":"98a4f025-5ee8-4f15-ae0b-6980e94aaeb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04238637","created_at":"2023-11-19T10:15:04.491Z","updated_at":"2025-02-25T15:09:02.238Z","phase":"Phase 2","brief_title":"Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)","source_id_and_acronym":"NCT04238637","lead_sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","biomarkers":" CD8 • PD-1 • CXCL10 • PD-L2 • CXCL9 • CXCL13 • CD68 • FOXP3 • MMP9 • LY75","pipe":" | ","alterations":" PD-L1 expression","tags":["CD8 • PD-1 • CXCL10 • PD-L2 • CXCL9 • CXCL13 • CD68 • FOXP3 • MMP9 • LY75"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 11/01/2019","start_date":" 11/01/2019","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-11-18"},{"id":"495ae210-14e3-4dc2-9bda-5e696bcb61a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT06056804","created_at":"2023-11-19T01:16:40.961Z","updated_at":"2024-07-02T16:35:28.894Z","phase":"Phase 2","brief_title":"Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer","source_id_and_acronym":"NCT06056804","lead_sponsor":"Beijing Friendship Hospital","biomarkers":" CD8 • CD163 • CD4 • CD68 • CD86","pipe":" | ","alterations":" CD163 expression • CD4 expression","tags":["CD8 • CD163 • CD4 • CD68 • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD163 expression • CD4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • capecitabine • Zadaxin (thymalfasin)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2023-11-17"},{"id":"83112f9b-4b22-4336-82d3-68d2e46ecb8f","acronym":"PRO-IMMUNO","url":"https://clinicaltrials.gov/study/NCT06016699","created_at":"2023-08-30T14:08:41.186Z","updated_at":"2024-07-02T16:35:38.551Z","phase":"","brief_title":"Immunological Function After Radiation With Either Proton or Photon Therapy","source_id_and_acronym":"NCT06016699 - PRO-IMMUNO","lead_sponsor":"University Medical Center Groningen","biomarkers":" CD20 • CD8 • PD-1 • CD163 • CD4 • CD68 • FOXP3","pipe":"","alterations":" ","tags":["CD20 • CD8 • PD-1 • CD163 • CD4 • CD68 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 09/23/2021","start_date":" 09/23/2021","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2023-08-30"},{"id":"fb8dc3ab-b4a9-4b4d-aae6-7233509f61b6","acronym":"Neo Combi","url":"https://clinicaltrials.gov/study/NCT01972347","created_at":"2021-03-01T20:52:35.949Z","updated_at":"2024-07-02T16:35:38.660Z","phase":"Phase 2","brief_title":"Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma","source_id_and_acronym":"NCT01972347 - Neo Combi","lead_sponsor":"Melanoma Institute Australia","biomarkers":" EGFR • CD20 • CD8 • PD-1 • CCND1 • MCL1 • IL6 • CTNNB1 • TNFA • CD163 • CD4 • IL10 • CD68 • IL18 • FOXP3 • CDKN1A","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["EGFR • CD20 • CD8 • PD-1 • CCND1 • MCL1 • IL6 • CTNNB1 • TNFA • CD163 • CD4 • IL10 • CD68 • IL18 • FOXP3 • CDKN1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 05/04/2017","primary_completion_date":" 05/04/2017","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2023-08-30"},{"id":"8bfb48a5-7a5e-4365-8828-e51c1648bb77","acronym":"ATPIC","url":"https://clinicaltrials.gov/study/NCT05867004","created_at":"2023-05-19T13:04:57.952Z","updated_at":"2024-07-02T16:35:47.091Z","phase":"","brief_title":"Blocking TNF to Potentiate the ICI-dependent Immune Awakening in Melanoma","source_id_and_acronym":"NCT05867004 - ATPIC","lead_sponsor":"Institut Claudius Regaud","biomarkers":" CD8 • IFNG • CD4 • CD14 • CD68 • FOXP3 • IL17A","pipe":" | ","alterations":" HLA-A2 positive","tags":["CD8 • IFNG • CD4 • CD14 • CD68 • FOXP3 • IL17A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A2 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 11/30/2023","primary_completion_date":" 11/30/2023","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-05-26"},{"id":"7e21b1c1-21f0-4b37-a171-fa51196f862e","acronym":"IMMUNIB","url":"https://clinicaltrials.gov/study/NCT03841201","created_at":"2021-01-18T18:57:47.456Z","updated_at":"2025-02-25T13:35:14.380Z","phase":"Phase 2","brief_title":"Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma","source_id_and_acronym":"NCT03841201 - IMMUNIB","lead_sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","biomarkers":" CD8 • PD-1 • CXCL10 • PD-L2 • CXCL9 • CXCL13 • CD68 • FOXP3 • MMP9 • LY75","pipe":"","alterations":" ","tags":["CD8 • PD-1 • CXCL10 • PD-L2 • CXCL9 • CXCL13 • CD68 • FOXP3 • MMP9 • LY75"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Lenvima (lenvatinib)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 06/12/2019","start_date":" 06/12/2019","primary_txt":" Primary completion: 10/27/2022","primary_completion_date":" 10/27/2022","study_txt":" Completion: 05/02/2023","study_completion_date":" 05/02/2023","last_update_posted":"2023-05-12"},{"id":"cc0ff819-00f0-4f9d-9b06-d419790f5cbd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04797468","created_at":"2022-10-26T18:06:23.272Z","updated_at":"2024-07-02T16:35:57.547Z","phase":"Phase 1","brief_title":"A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor","source_id_and_acronym":"NCT04797468","lead_sponsor":"Shanghai Henlius Biotech","biomarkers":" CD68","pipe":"","alterations":" ","tags":["CD68"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLX23"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/18/2022","start_date":" 07/18/2022","primary_txt":" Primary completion: 01/13/2023","primary_completion_date":" 01/13/2023","study_txt":" Completion: 01/13/2023","study_completion_date":" 01/13/2023","last_update_posted":"2023-01-16"},{"id":"d45ba617-287d-4d20-b7f9-60232b733564","acronym":"","url":"https://clinicaltrials.gov/study/NCT04065555","created_at":"2021-02-12T16:54:14.811Z","updated_at":"2025-02-25T14:51:31.104Z","phase":"Phase 1","brief_title":"Intratumoral Microdosing of TAK-981 in Head and Neck Cancer","source_id_and_acronym":"NCT04065555","lead_sponsor":"Presage Biosciences","biomarkers":" CD8 • NCAM1 • CASP3 • CD68 • GZMB • CD86","pipe":"","alterations":" ","tags":["CD8 • NCAM1 • CASP3 • CD68 • GZMB • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Bavencio (avelumab) • subasumstat (TAK-981)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 10/07/2020","start_date":" 10/07/2020","primary_txt":" Primary completion: 06/20/2022","primary_completion_date":" 06/20/2022","study_txt":" Completion: 07/20/2022","study_completion_date":" 07/20/2022","last_update_posted":"2022-07-29"}]